Nektar takes a hit as the FDA swerves away from opioid reviews — leaving NKTR-181 in limbo
Nektar Therapeutics took another hit on Thursday after the biotech reported that its opioid pain drug NKTR-181 was being put on hold at the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.